OBJECTIVE： To study the effects of salvianolate on the expression of vascular endothelial growth factor （VEGF） and matrix metalloproteinase-9 （MMP-9） in lung tissue of mice with lung cancer. METHODS： C57BL/6 mice were randomly divided into model group （normal saline）， positive control group （cyclophosphamide 50 mg/kg） and salvianolate low-dose， medium-dose and high-dose groups （20， 40， 80 g/kg） with 10 mice in each group. They were ig 1 000 mg/kg urethane， twice a day， for consecutive 4 weeks to establish lung cancer model. After modeling， they were given relevant medicine intragastrically once a day for consecutive 14 d. Mice behaviors， symptoms， body weight， tumor inhibition rate， spleen index， thymus index， and the expressions of VEGF and MMP-9 in lung tissue among groups were compared. RESULTS： The activity of mice in model group disappeared， dull coat color， preferred crowding together； the above-mentioned phenomenon improved in positive control group and salvianolate different dose groups. The body weight of mice in positive control group， salvianolate low-dose group， medium-dose group and high-dose group were （21.01±2.95） g， （20.89±3.14） g， （21.03±3.02） g， （21.24±3.17） g； and the tumor inhibition rates were （41.12±15.42）％， （36.92±10.42）％， （39.41±12.39）％ and （37.19±10.39）％； compared with model group， spleen index， thymus index， and the expressions of VEGF （except for positive control group） and MMP-9 in other 4 groups decreased （P＜0.05）. CONCLUSIONS： Salvianolate shows obvious inhibitory effects on mice with lung cancer， which may be related to inhibiting expressions of VEGF and MMP-9 in lung tissue.